Using a new blood substitute to reduce brain damage in stroke patients
Mitigation of Cerebral Infarct Growth in Acute Ischemic Stroke Using a Novel Blood Substitute
This study is looking at a new treatment called Sanguinate® that could help reduce brain damage during a stroke by improving blood flow and oxygen delivery to the affected areas, and it’s designed for people who are having a stroke.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10944298 on NIH RePORTER |
What this research studies
This research investigates the use of a novel biopharmaceutical agent called Sanguinate® to mitigate the growth of brain damage during acute ischemic strokes. The study focuses on how this blood substitute can enhance blood flow and oxygen delivery to brain tissues that are deprived of oxygen, which is critical in the early stages of a stroke. By improving collateral blood circulation and delivering oxygen directly to affected areas, the research aims to reduce the size of brain infarcts and minimize injury during treatment. Patients experiencing strokes may benefit from this innovative approach that targets the underlying mechanisms of brain injury.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals experiencing acute ischemic strokes, particularly those with varying degrees of collateral blood circulation.
Not a fit: Patients who have experienced hemorrhagic strokes or those with contraindications to the use of blood substitutes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce brain damage and improve recovery outcomes for stroke patients.
How similar studies have performed: Previous research has shown promise in using blood substitutes for improving oxygen delivery in ischemic conditions, suggesting potential for success in this novel application.
Where this research is happening
Chicago, United States
- University of Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Carroll, Timothy J — University of Chicago
- Study coordinator: Carroll, Timothy J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.